Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2019-03-07
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 8
- Registration Number
- NCT02497378
A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-07-13
- Last Posted Date
- 2021-09-10
- Lead Sponsor
- University of Heidelberg Medical Center
- Target Recruit Count
- 564
- Registration Number
- NCT02495922
- Locations
- 🇩🇪
Schwarzwald-Baar Klinikum, Klinik für Innere Medizin II, Villingen-Schwenningen, Germany
🇩🇪Rems-Murr-Klinikum gGmbH Winnenden, Winnenden, Germany
🇩🇪Studienzentrum Aschaffenburg, Aschaffenburg, Germany
Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib
- Conditions
- Interventions
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Boston Medical Center
- Target Recruit Count
- 3
- Registration Number
- NCT02489500
- Locations
- 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children
- First Posted Date
- 2015-06-29
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Reuven Schore
- Target Recruit Count
- 10
- Registration Number
- NCT02484261
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-06-25
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Joaquín Martínez López, MD, PhD
- Target Recruit Count
- 5
- Registration Number
- NCT02481934
- Locations
- 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma
- First Posted Date
- 2015-06-17
- Last Posted Date
- 2015-06-30
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 171
- Registration Number
- NCT02474563
Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance
- Conditions
- Interventions
- First Posted Date
- 2015-06-09
- Last Posted Date
- 2015-06-09
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 73
- Registration Number
- NCT02467010
- Locations
- 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 46
- Registration Number
- NCT02441686
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Virginia Piper Cancer Institute, Coon Rapids, Minnesota, United States
🇺🇸Massachusetts General Hosptial, Boston, Massachusetts, United States
Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
- Conditions
- Interventions
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2023-01-04
- Target Recruit Count
- 57
- Registration Number
- NCT02440464
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸University of Texas /MD Anderson CRC, Houston, Texas, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
Optimising Renal Outcome in Myeloma Renal Failure
- Conditions
- Interventions
- First Posted Date
- 2015-04-23
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Oxford University Hospitals NHS Trust
- Target Recruit Count
- 31
- Registration Number
- NCT02424851
- Locations
- 🇬🇧
Kent & Canterbury Hospital, Canterbury, United Kingdom
🇬🇧Royal Liverpool Hospital, Liverpool, United Kingdom
🇬🇧Heartlands Hospitals, Birmingham, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.